The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer.

BACKGROUND We examined the clinical relevance of skeletal-related events (SREs) for health state preferences, pain and health-related quality of life in patients with advanced prostate cancer and a history of bone metastases. PATIENTS AND METHODS Data were from a clinical trial of zoledronic acid versus placebo in the treatment of SREs associated with advanced prostate cancer metastatic to bone. Patients (n=248) were included if they experienced an SRE during the study. Outcome measures were assessed at fixed intervals. We used mixed-effects models to estimate changes in outcomes after each patient's first SRE. RESULTS There were clinically meaningful and statistically significant declines in physical well-being after: radiation and pathologic fractures; functional well-being after radiation; and emotional well-being after radiation and pathologic fractures. There also were meaningful and significant declines in preference and utility scores after radiation and fracture. Pain intensity declined after radiation, but not after other SREs; no other pain measure changed substantively. CONCLUSIONS SREs have important and significant effects on measures of health-related quality of life in men with prostate cancer. Treatments that prevent SREs may not demonstrate corresponding effects on outcomes if the effects of SREs occur between scheduled outcome assessments. Implications for trial design are discussed.

[1]  C. D. Atkins Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2003, Journal of the National Cancer Institute.

[2]  A. Kasuya EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.

[3]  D. Tulsky,et al.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Cleeland,et al.  Validation of the German version of the Brief Pain Inventory. , 1999, Journal of pain and symptom management.

[5]  M. Jensen,et al.  Pain‐Specific Beliefs, Perceived Symptom Severity, and Adjustment to Chronic Pain , 1992, The Clinical journal of pain.

[6]  K. Pienta,et al.  Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. , 1997, Urology.

[7]  R H Brook,et al.  Quality-of-life outcomes in men treated for localized prostate cancer. , 1995, JAMA.

[8]  A. Williams EuroQol : a new facility for the measurement of health-related quality of life , 1990 .

[9]  L. Dogliotti,et al.  Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. , 2000, The Journal of urology.

[10]  C. Cleeland,et al.  Pain assessment: global use of the Brief Pain Inventory. , 1994, Annals of the Academy of Medicine, Singapore.

[11]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[12]  R. Pelger,et al.  Strategies for Management of Prostate Cancer-Related Bone Pain , 2001, Drugs & aging.

[13]  H. Villavicencio Quality of life of patients with advanced and metastatic prostatic carcinoma. , 1993, European urology.

[14]  G. Andriole,et al.  The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma , 2000, Cancer.

[15]  Ana Ivelisse Avilés,et al.  Linear Mixed Models for Longitudinal Data , 2001, Technometrics.

[16]  P. Lachenbruch Statistical Power Analysis for the Behavioral Sciences (2nd ed.) , 1989 .

[17]  K. Anstrom,et al.  Effect of zoledronic acid on clinically meaningful changes in pain associated with metastatic prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  H. Libshitz,et al.  Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases. , 1998, Journal of pain and symptom management.

[19]  P. Dolan,et al.  Modeling valuations for EuroQol health states. , 1997, Medical care.

[20]  M. Rosenthal Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2003, Journal of the National Cancer Institute.